Kolon Life Science Inc. (KOSDAQ:102940)

Market Cap	190.60B -47.2%
Revenue (ttm)	211.44B +17.1%
Net Income	34.63B
EPS	2,403.02
Shares Out	13.09M
PE Ratio	6.06
Forward PE	n/a
Dividend	2.65 (0.02%)
Ex-Dividend Date	n/a

Volume	58,915
Open	14,890
Previous Close	14,700
Day's Range	14,500 - 14,920
52-Week Range	13,210 - 72,700
Beta	0.20
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Kolon Life Science

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ...

• Industry: Chemicals
• Sector: Materials
• Founded: 2000
• Employees: 425
• Stock Exchange: KOSDAQ
• Ticker Symbol: 102940

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 3, 2026

Data Sources Report a data error